Status:
ACTIVE_NOT_RECRUITING
Quercetin in Coronary Artery By-pass Surgery
Lead Sponsor:
Montreal Heart Institute
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery.
Detailed Description
After being informed about the study and the potential risk, all patients giving written informed consent will be randomized in a double-blind manner (participant and investigators) on 1:1 ratio to re...
Eligibility Criteria
Inclusion
- to be able to speak French or English;
- to be able to give free and enlighten consent;
- be hospitalized and waiting for a cardiac surgery of revascularization;
- to have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery.
Exclusion
- to be in a stable state without MI in the last 30 days;
- have a cardiac surgery concomitant to the cardiac surgery of revascularization;
- have an infection in the last 30 days;
- to have renal insufficiency (GFR less than 30);
- to have a liver disease (AST, ALT or bilirubin ˃ 2X normal values);
- to have a known cirrhosis;
- to have a past history of breast cancer or other tumors estrogen-dependent;
- to be intolerant to flavonoids, niacine or ascorbic acid;
- take quinolone;
- need for a quinolone during post-op;
- not being able to give a free and enlighten consent;
- not being able to speak French of English;
- take quercetin as a supplement.
Key Trial Info
Start Date :
June 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04907253
Start Date
June 4 2021
End Date
September 1 2025
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montreal Heart Institute
Montreal, Quebec, Canada, H1T 1C8